💊Takeda and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device  2017年11月7日

medical service

💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)

Cancer, FDA

👾Diabetes in China 〜 Publications / by Swiss Re

Insurance, medical service

🔬RIKEN develops a technology to distinguish the interphase of the cell cycle (G1 · S · G2) by three colors     20171027

IPS

Posts navigation